Search results for " Modality"

showing 10 items of 461 documents

Treatment of soft tissue sarcoma in childhood and adolescence: A report of the german cooperative soft tissue sarcoma study

1992

Background In the first German soft tissue sarcoma (STS) study, CWS-81, 344 patients younger than 19 years of age who had previously untreated soft tissue sarcoma were studied. For this analysis, there were 218 patients with chemosensitive STS (Group A: rhabdomyosarcoma [RMS], synovial sarcoma, extraosseous Ewing sarcoma, leiomyosarcoma, undifferentiated sarcoma, and malignant peripheral neuroectodermal tumor) who could be studied for a minimum potential follow-up time of 6 years. Methods A staging system based on the postoperative extent of the disease was used. The chemotherapy for Stage I-III disease consisted of vincristine, dactinomycin, cyclophosphamide, and doxorubicin (VACA). Patien…

MaleReoperationLeiomyosarcomaCancer Researchmedicine.medical_specialtyVincristineAdolescentmedicine.medical_treatmentSoft Tissue NeoplasmsGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildRhabdomyosarcomaCyclophosphamideSurvival rateNeoplasm StagingChemotherapybusiness.industrySoft tissue sarcomaSarcomaPrognosismedicine.diseaseCombined Modality TherapySurvival AnalysisSynovial sarcomaSurgeryOncologyChemotherapy AdjuvantDoxorubicinVincristineChild PreschoolDactinomycinRegression AnalysisFemaleSarcomabusinessFollow-Up Studiesmedicine.drugCancer
researchProduct

Transgraft sac Embolization Combined with Graft Reinforcement for Refractory Mixed-Type Endoleak.

2018

International audience; An 80-year-old female underwent EVAR 4 years ago. She presented type II endoleak with sac expansion from 68 to 80 mm during 3-year follow-up after EVAR. Although she underwent translumbar percutaneous sac embolization, the AAA sac continued to enlarge, suggesting mixed-type endoleak including type I, II, and III. Transgraft direct sac angiography revealed endoleak cavity without demonstrable feeding vessel. Transgraft sac embolization using n-butyl cyanoacrylate and graft reinforcement was performed concurrently, without complications. The graft reinforcement consisted of graft extension for eliminating occult type I endoleak, and relining for eliminating occult type…

MaleReoperationmedicine.medical_specialtyTransgraft sac embolizationPercutaneousEndoleakmedicine.medical_treatmentMixed typeAortographyGraft reinforcement030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciencesBlood Vessel Prosthesis Implantation0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRefractoryMixed-type endoleaklawn-butyl cyanoacrylatemedicineHumansEVARRadiology Nuclear Medicine and imagingEmbolizationAged[SDV.IB] Life Sciences [q-bio]/BioengineeringAged 80 and overmedicine.diagnostic_testbusiness.industryN-butyl-cyanoacrylateEndovascular ProceduresEnbucrilateCombined Modality TherapyEmbolization Therapeutic[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemSurgeryTreatment OutcomeCyanoacrylateAngiography[SDV.IB]Life Sciences [q-bio]/BioengineeringFemaleStentsCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedAortic Aneurysm AbdominalCardiovascular and interventional radiology
researchProduct

Rare association of herpes simplex virus IgM-specific antibodies and Guillain-Barré syndrome successfully treated with plasma exchange and immunosupp…

1985

Herpes simplex virus (HSV) has been associated with various neurological disorders. In contrast, HSV infection is very rarely found in acute polyneuroradiculitis. In this report, a patient is described with a severe course of Guillain-Barr¿ syndrome (GBS). HSV IgM-specific antibodies and a rise of complement-fixation antibodies were detected. During the acute phase of neurologic syndrome, a nerve biopsy showed myelin damage and IgM deposits on the inner layer of the perineurium. Plasma exchange, in combination with immunosuppression, was successfully applied as a treatment in the relapsing course of GBS. Finally, after recovery, HSV-specific IgM antibodies disappeared.

MaleSimplexvirusfood.ingredientBiopsyPrednisolonevirusesmedicine.medical_treatmentNeural ConductionPolyradiculoneuropathyAntibodies Viralmedicine.disease_causefoodSural NerveAntibody SpecificityAzathioprineDrug DiscoverymedicineHumansSimplexvirusGenetics (clinical)AgedNerve biopsyPlasma ExchangeGuillain-Barre syndromemedicine.diagnostic_testbiologyHerpes SimplexImmunosuppressionPolyradiculoneuropathyGeneral Medicinemedicine.diseaseCombined Modality TherapyVirologyHerpes simplex virusImmunoglobulin MImmunoglobulin MImmunologybiology.proteinMolecular MedicineAntibodyKlinische Wochenschrift
researchProduct

Detrimental Effects of 60 kHz Sonothrombolysis in Rats with Middle Cerebral Artery Occlusion

2008

Recent studies have raised concerns about the safety of low frequency ultrasound in transcranial therapeutic application in cerebral ischemia. This study was designed to evaluate safety aspects and potential deleterious effects of low frequency, 60 kHz ultrasound in treatment of experimental middle cerebral artery occlusion (MCAO) in rats. Forty-five male Wistar rats were submitted to either temporary (90 min; groups I and II) or permanent MCAO (groups III and IV) using the suture technique. All animals received recombinant tissue plasminogen activator (rt-PA) starting 90 min after the beginning of occlusion. Groups I and III were additionally treated with 60 kHz ultrasound (time average ac…

MaleSubarachnoid hemorrhageAcoustics and UltrasonicsUltrasonic Therapymedicine.medical_treatmentBiophysicsIschemiaOcclusionmedicineAnimalsThrombolytic TherapyRadiology Nuclear Medicine and imagingRats WistarHearing DisordersStrokeCerebral HemorrhageRadiological and Ultrasound TechnologyTherapeutic ultrasoundmedicine.diagnostic_testbusiness.industryUltrasoundTemperatureInfarction Middle Cerebral ArteryMagnetic resonance imagingSubarachnoid Hemorrhagemedicine.diseaseCombined Modality TherapyMagnetic Resonance ImagingRatsTreatment OutcomeAnesthesiabusinessPerfusionUltrasound in Medicine & Biology
researchProduct

Rationale and results of the international society of pediatric oncology (SIOP) Italian pilot study on childhood hepatoma: Surgical resectionD'Emblée…

1993

MaleSurgical resectionPediatricsmedicine.medical_specialtyCarcinoma HepatocellularAdolescentBiopsyPilot ProjectsChildhood HepatomaAntineoplastic Combined Chemotherapy ProtocolsPreoperative CarePediatric oncologymedicineHepatectomyHumansPrimary chemotherapyChildbusiness.industryLiver NeoplasmsRemission InductionInfantGeneral MedicineCombined Modality TherapySurvival RateItalyOncologyDoxorubicinChild PreschoolFemaleSurgeryCisplatinbusinessFollow-Up StudiesJournal of Surgical Oncology
researchProduct

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspi…

2009

The prognosis for thalassemia major has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop progressive accumulation of iron. This can lead to tissue damage and eventually death, particularly from cardiac disease. Previous studies that investigated iron chelation treatments, including retrospective and prospective non-randomised clinical trials, suggested that mortality, due mainly to cardiac damage, was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment. However, no survival analysis has been reported for a long-term randomised control …

MaleThalassemiaKaplan-Meier Estimatelaw.inventionchemistry.chemical_compoundRandomized controlled triallawCause of DeathNeoplasmsDeferiproneProspective StudiesChildCause of deathHazard ratioHematologyMiddle AgedCombined Modality TherapySurvival RateThalassemia survival chelation treatment trial thalassemia majorCombinationSplenectomyMolecular MedicineDrug Therapy CombinationFemaleDeferiproneAdultmedicine.medical_specialtyAdolescentPyridonesDeferoxamineIron Chelating AgentsYoung AdultDrug TherapyInternal medicinemedicineHumansBlood TransfusionAdolescent; Adult; Blood Transfusion; Cause of Death; Chelation Therapy; Child; Combined Modality Therapy; Deferoxamine; Drug Therapy; Combination; Female; Heart Failure; Humans; Iron Chelating Agents; Kaplan-Meiers Estimate; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Prospective Studies; Pyridones; Splenectomy; Survival Rate; Young Adult; beta-ThalassemiaMolecular BiologySurvival rateKaplan-Meiers EstimateSurvival analysisProportional Hazards ModelsHeart Failurebusiness.industryProportional hazards modelbeta-ThalassemiaCell Biologymedicine.diseaseChelation TherapySurgerychemistrybusiness
researchProduct

Augmentation of tibial plateau fractures with an injectable bone substitute: CERAMENT™. Three year follow-up from a prospective study

2015

Background: Reduction of tibial plateau fractures and maintain a level of well aligned congruent joint is key to a satisfactory clinical outcome and is important for the return to pre-trauma level of activity. Stable internal fixation support early mobility and weight bearing. The augmentation with bone graft substitute is often required to support the fixation to mantain reduction. For these reasons there has been development of novel bone graft substitutes for trauma applications and in particular synthetic materials based on calcium phosphates and/or apatite combined with calcium sulfates. Injectable bone substitutes can optimize the filling of irregular bone defects. The purpose of this…

MaleTime FactorsPercutaneousKnee Jointmedicine.medical_treatmentDentistryFracture Fixation InternalFracture FixationTibial plateau fracture Surgical treatment Bone graft Ceramic injectable biphasic bone substitute Clinical and radiographic outcomeFracture fixationTibial plateau fractureOrthopedics and Sports MedicineProspective StudiesTomographyFracture HealingSurgical treatmentBone TransplantationMiddle AgedCombined Modality TherapyBiomechanical PhenomenaX-Ray ComputedDrug CombinationsTreatment Outcomemedicine.anatomical_structureSettore MED/03FemaleResearch ArticleAdultmedicine.medical_specialtyBone healingCalcium SulfateInjectionsRheumatologyClinical and radiographic outcomeTibial plateau fracturemedicineBone graftHumansInternal fixationTibiaTibiabusiness.industryRecovery of Functionmedicine.diseaseInternalSurgeryTibial FracturesDurapatiteCeramic injectable biphasic bone substituteIrregular boneBone SubstitutesOrthopedic surgeryAdult; Biomechanical Phenomena; Bone Substitutes; Bone Transplantation; Calcium Sulfate; Combined Modality Therapy; Drug Combinations; Durapatite; Female; Follow-Up Studies; Fracture Fixation Internal; Fracture Healing; Humans; Injections; Knee Joint; Male; Middle Aged; Prospective Studies; Recovery of Function; Tibia; Tibial Fractures; Time Factors; Tomography X-Ray Computed; Treatment OutcomeTomography X-Ray ComputedbusinessFollow-Up StudiesBMC Musculoskeletal Disorders
researchProduct

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-h…

2015

AbstractObjectiveLomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data from a Phase 3 study to assess whether concomitant apheresis affected the lipid-lowering efficacy of lomitapide.MethodsExisting lipid-lowering therapy, including apheresis, was to remain stable from Week −6 to Week 26. Lomitapide dose was escalated on the basi…

MaleTime FactorsSettore MED/09 - Medicina InternaGastroenterologyMicrosomal triglyceride transfer proteinchemistry.chemical_compoundLipoprotein apheresisMedicineHyperlipoproteinemia Type IIHomozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Biomarkers; Blood Component Removal; Cholesterol LDL; Combined Modality Therapy; Female; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Phenotype; Time Factors; Treatment Outcome; Young Adult; Homozygote; Cardiology and Cardiovascular MedicinebiologyAnticholesteremic AgentsHomozygoteLipoprotein(a)Combined Modality TherapyCholesterolPhenotypeTreatment OutcomeBlood Component Removallipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySocio-culturaleLipoprotein apheresiArticleLDLHyperlipoproteinemia Type IIYoung AdultHomozygous familial hypercholesterolaemiaInternal medicinePost-hoc analysisHumansGenetic Predisposition to DiseaseHomozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide; Cardiology and Cardiovascular Medicinebusiness.industryCholesterol LDLLomitapideLomitapideEndocrinologyApheresischemistryConcomitantAdjunctive treatmentbiology.proteinBenzimidazolesbusinessBiomarkersLipoprotein(a)Atherosclerosis
researchProduct

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular ede…

2013

To evaluate the anatomical and functional outcomes at 24 months in patients with diffuse diabetic macular edema treated with primary intravitreal bevacizumab (IVB) plus grid laser photocoagulation (GLP) or primary IVB alone or GLP alone.Retrospective, interventional, comparative, multicenter study. We included in this analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with primary IVB alone (Group A), 120 eyes of 94 patients with GLP therapy (Group B), and 157 eyes of 104 patients treated with IVB plus GLP (Group C).In all 3 groups, the authors observed improvement of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity from baseline to 24-month…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresDiabetic macular edemaVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular EdemaOphthalmologymedicineHumansIn patientIntravitreal bevacizumabRetrospective StudiesRetinaDiabetic RetinopathyLaser Coagulationbusiness.industryGeneral MedicineMiddle AgedCombined Modality Therapyeye diseasesbody regionsBevacizumabOphthalmologymedicine.anatomical_structureTreatment OutcomeIntravitreal InjectionsFemalesense organsbusinessTomography Optical CoherenceRetina (Philadelphia, Pa.)
researchProduct

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention …

2019

Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y 12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI,…

MaleVitamin Kmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicineAntithromboticAtrial Fibrillation//purl.org/pe-repo/ocde/ford#3.02.04 [https]030212 general & internal medicineProspective Studies610 Medicine & healthAspirinVKADisease ManagementAtrial fibrillationVitamin K antagonistMiddle AgedCombined Modality TherapyHospitalizationTreatment Outcomesurgical procedures operativeElective Surgical ProceduresCardiologyApixabanDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyAcute coronary syndromemedicine.drug_classPyridonesDOACHemorrhageP2Y12 inhibitor03 medical and health sciencesPercutaneous Coronary InterventionFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeAgedProportional Hazards ModelsAspirinbusiness.industryPercutaneous coronary interventionAnticoagulantsCardiovascular Agentsmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsPyrazolesbusinessPlatelet Aggregation Inhibitors
researchProduct